Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.4.3 to v3.5.0. No changes to study content are evident in the screenshot.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedFooter revision updated to v3.4.3; the previous v3.4.2 label was removed.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedFooter now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision reflects an update from v3.4.0 to v3.4.1 with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedAdded Show glossary / Hide glossary options and updated metadata labels to reflect Revision: v3.4.0 (Last Update Submitted that Met QC Criteria; No FEAR Act Data).SummaryDifference0.3%

- Check66 days agoChange DetectedRevision: v3.3.4 appears alongside the previous v3.3.3 revision, indicating a small maintenance update with no impact on the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.